TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26698306

Group type: EXPERIMENTAL
Intervention: Breath VOC mass ion biomarkers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Breath VOC mass ion biomarkers at Laboratory A
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Breath VOC mass ion biomarkers at Laboratory B
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of breath biomarkers with chest CT
Number of subjects: 70
Study: 26698309

Group type: EXPERIMENTAL
Intervention: Adho Mukha Svanasana
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uttanasana
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Halasana
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Viparita Karani
Number of subjects: 20
Study: 26698868

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) at doses of up to 300 mg/m(2) over 4 hours
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) of nab-paclitaxel over 1 hour
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hepatic arterial infusion (HAI) of nab-paclitaxel
Number of subjects: 48
Study: 26698910

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 1

Group type: COMPARATOR
Intervention: Lorlatinib
Number of subjects: 1
Study: 26699604

Group type: EXPERIMENTAL
Intervention: Renal denervation using the Symplicity Spyral multielectrode renal denervation catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study: 26699672

Group type: EXPERIMENTAL
Intervention: P-Vrs curve
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EELV-Cst,rs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CT (not inflated)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CT (not + poorly inflated)
Number of subjects: 22
Study: 26699701

Group type: EXPERIMENTAL
Intervention: Urine Galactomannan-to-Creatinine Ratio
Number of subjects: 71
Study: 26700120

Group type: EXPERIMENTAL
Intervention: Web-based educational tool (Preparatory Education About Clinical Trials)
Number of subjects: 1211
Study: 26700485

Group type: EXPERIMENTAL
Intervention: TSH-suppressive LT4 doses
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: LT4 replacement therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: LT4 euthyroid women
Number of subjects: 122
Study: 26700706

Group type: EXPERIMENTAL
Intervention: Short course of hypofractionated whole-breast irradiation (WBI) with a boost: 36.63 Gy in 11 fractions of 3.33 Gy over 11 days, followed by a lumpectomy bed boost in 4 fractions of 3.33 Gy
Number of subjects: 83
Study: 26701602

Group type: COMPARATOR
Intervention: Recombinant full-length P. vivax ectodomains
Number of subjects: 34
Study: 26701835

Group type: EXPERIMENTAL
Intervention: Standardized self-report questionnaires for HRQoL and mental health assessment
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Time since child's acute HUS episode
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Diagnosis of PTSD
Number of subjects: 121
Study: 26701919

Group type: EXPERIMENTAL
Intervention: Implant-supported therapy
Number of subjects: 588
Study: 26702094

Group type: EXPERIMENTAL
Intervention: VRC01 (single dose) in ART-untreated subjects
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: VRC01 (two infusions) in ART-treated subjects
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: VRC01 (single dose) in ART-untreated subjects with plasma virus load <1000 copies/ml
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: VRC01 (single dose) in ART-untreated subjects with baseline virus loads between 3000 and 30,000 copies
Number of subjects: 14
Study: 26702147

Group type: EXPERIMENTAL
Intervention: Diamondback 360® Coronary Orbital Atherectomy System (OAS)
Number of subjects: 0
Study: 26702637

Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccination at age 6, 10 and 14 weeks with DTP3 coverage
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccination at age 6, 7-and-a-half and 9 months with 75% DTP3 coverage
Number of subjects: 42
Study: 26702763

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 26702865

Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 97
Study: 26702925

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (600 mg every 12 h)
Number of subjects: 1916

Group type: COMPARATOR
Intervention: Ceftriaxone (1-2 g every 24 h)
Number of subjects: 1916
Study: 26704020

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg per day for 3 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Azithromycin (early initiation before day 6)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Azithromycin (initiation on or after day 6)
Number of subjects: 72
Study: 26704148

Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Simeprevir + sofosbuvir
Number of subjects: 103
Study: 26704626

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg single dose
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/day for 4 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 66
Study: 26704864

Group type: EXPERIMENTAL
Intervention: Plasma PAI-1 levels
Number of subjects: 39
Study: 26705752

Group type: EXPERIMENTAL
Intervention: Rest and Exercise Adaptation
Number of subjects: 0
Study: 26706103

Group type: EXPERIMENTAL
Intervention: (177)Lu-girentuximab, 2405 MBq/m(2) intravenously, with retreatment after 3 months at 75% of the previous dose if no persistent toxicity or progressive disease.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: (177)Lu-girentuximab
Number of subjects: 14
Study: 26706294

Group type: EXPERIMENTAL
Intervention: Three-injection intralymphatic immunotherapy
Number of subjects: 0
Study: 26706812

Group type: EXPERIMENTAL
Intervention: Substance use (SU)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Substance use disorders (SUD)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Health indicators
Number of subjects: 52
Study: 26707232

Group type: EXPERIMENTAL
Intervention: Pressure to be thin
Number of subjects: 215
Study: 26707935

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) + Venetoclax (ABT-199)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venetoclax (ABT-199) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) + Melphalan or Carfilzomib
Number of subjects: 0
Study: 26708155

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg orally twice daily until progression, death, or withdrawal.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 87
Study: 26708172

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Clinical judgment regarding myocardial ischemia
Number of subjects: 403

Group type: COMPARATOR
Intervention: Pharmacological stress
Number of subjects: 403
Study: 26708830

Group type: EXPERIMENTAL
Intervention: venlafaxine XR monotherapy for up to 16 weeks
Number of subjects: 468
Study: 26708836

Group type: EXPERIMENTAL
Intervention: Various behavioral and lifestyle interventions
Number of subjects: 0
Study: 26709883

Group type: EXPERIMENTAL
Intervention: HBV immunoglobulin and complete vaccine
Number of subjects: 35

Group type: COMPARATOR
Intervention: No intervention (negative for HBsAg, HBsAb, and HBcAb)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (lamivudine or tenofovir/emtricitabine) during pregnancy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Incomplete vaccine
Number of subjects: 35
Study: 26709970

Group type: EXPERIMENTAL
Intervention: Resting Energy Expenditure (REE) in PHP1A participants
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group of obese participants
Number of subjects: 12
Study: 26710961

Group type: EXPERIMENTAL
Intervention: Lorazepam (one or two doses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lorazepam (second double dose)
Number of subjects: 33
Study: 26711162

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Cold Turkey
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Stress as a precipitator of relapse
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Health as motivation for quit attempt
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Family/Social pressures as motivation
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Cost as motivation
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Cravings as pre-cessation concern
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Stress as pre-cessation concern
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Fear of failure as pre-cessation concern
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Concerns about cravings in participants with psychotic and anxiety disorders
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Concerns about stress and fear of failure in participants with anxiety
Number of subjects: 732
Study: 26711546

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) prescription at discharge
Number of subjects: 2894
Study: 26711747

Group type: EXPERIMENTAL
Intervention: ABT-493 (doses ranging from 100 mg to 700 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ABT-530 (doses of ≥ 40 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ABT-493
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ABT-530
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ABT-493 and ABT-530
Number of subjects: 40
Study: 26711756

Group type: EXPERIMENTAL
Intervention: 2 g Azithromycin (AZI) given during labor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Azithromycin in breast milk
Number of subjects: 20
Study: 26711775

Group type: EXPERIMENTAL
Intervention: 1 g doripenem every 8 h
Number of subjects: 13
Study: 26711777

Group type: EXPERIMENTAL
Intervention: AFN-1252, 200 mg given by mouth twice daily
Number of subjects: 103
Study: 26711792

Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymphadenectomy (MILND) after a structured training program
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymphadenectomy (MILND)
Number of subjects: 88
Study: 26712084

Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg
Number of subjects: 1034

Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg (in patients with at least 50% PD-L1 expression)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg (in patients with at least 50% PD-L1 expression)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: docetaxel (in patients with at least 50% PD-L1 expression)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 1034
Study: 26712110

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 2809
Study: 26712327

Group type: EXPERIMENTAL
Intervention: Combination of therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expensive biologic drug
Number of subjects: 0
Study: 26712453

Group type: EXPERIMENTAL
Intervention: Baseline body mass index (BMI)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) cholesterol
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Family history of diabetes (FHD)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Baseline risk markers
Number of subjects: 94
Study: 26714500

Group type: EXPERIMENTAL
Intervention: High physical activity (cpm > 31)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low physical activity (cpm ≤ 31)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High physical activity (cpm > 31) in patients with diabetes
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low physical activity (cpm ≤ 31) in patients with diabetes
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High physical activity (cpm > 31) in controls
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low physical activity (cpm ≤ 31) in controls
Number of subjects: 200
Study: 26714738

Group type: EXPERIMENTAL
Intervention: TNFα inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNFα stimulation in T cells from healthy controls (HC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bryostatin-1 experiments
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNFα
Number of subjects: 0
Study: 26714769

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care for 1 year
Number of subjects: 40
Study: 26714807

Group type: EXPERIMENTAL
Intervention: Airway Medix Closed Suction System™, cleaning group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (no ETT cleaning, standard closed suction), control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 26715442

Group type: EXPERIMENTAL
Intervention: Chemotherapy-related toxicities (severe neutropenia grades ≥3)
Number of subjects: 6248

Group type: EXPERIMENTAL
Intervention: Chemotherapy-related toxicities (fatigue grades ≥3)
Number of subjects: 6248

Group type: EXPERIMENTAL
Intervention: NEAT/BR9601 sub-group analysis (fatigue grades ≥3)
Number of subjects: 6248
Study: 26715447

Group type: EXPERIMENTAL
Intervention: 6-month guided weight loss intervention (twice weekly classes and text messaging)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Self-guided weight loss intervention (based on the same materials as the guided program)
Number of subjects: 240
Study: 26715570

Group type: EXPERIMENTAL
Intervention: Cardiac MRI (CMR) based feature tracking (FT) measuring longitudinal (LS), circumferential (CS), and radial global strain (RS)
Number of subjects: 372
Study: 26715573

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg orally daily, gemcitabine 1000 mg/m2 intravenously on days 1, 8, 15, and capecitabine 850 mg/m2 orally twice daily on days 1-21.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vandetanib 200 mg orally daily (during dose escalation phase).
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of gemcitabine, capecitabine, and vandetanib.
Number of subjects: 23
Study: 26716164

Group type: EXPERIMENTAL
Intervention: Inpatient non-cardiac surgery
Number of subjects: 3927

Group type: EXPERIMENTAL
Intervention: Urgent or emergency surgical procedures
Number of subjects: 3927
Study: 26717401

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB) assessment via apnea/hypopnea index (AHI) > 5/h
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS) assessment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mainz Severity Score Index (MSSI) assessment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multivariable analysis of predictors of SDB
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Association of ESS with depression
Number of subjects: 62
Study: 26717526

Group type: EXPERIMENTAL
Intervention: Citalopram at a dose of 20-60 mg/d for 12 weeks
Number of subjects: 3984
Study: 26717906

Group type: EXPERIMENTAL
Intervention: Tablet-based e-workbook for child mental health treatment
Number of subjects: 20
Study: 26718090

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy (target SpO2 88-92% using the lowest FiO2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 100
Study: 26718413

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Formula Feeding (FF)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Mixed Feeding (MF)
Number of subjects: 932
Study: 26718501

Group type: EXPERIMENTAL
Intervention: SLC19A3 SNPs
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Meta-analysis including WESDR cohort
Number of subjects: 134
Study: 26718690

Group type: EXPERIMENTAL
Intervention: Seroprevalence of pertussis antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current or recent infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pertussis prevalence by demographics
Number of subjects: 0
Study: 26718759

Group type: EXPERIMENTAL
Intervention: Iohexol plasma clearance
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 43

Group type: COMPARATOR
Intervention: Creatinine-based renal function estimating equations
Number of subjects: 43
Study: 26719427

Group type: EXPERIMENTAL
Intervention: Higher baseline levels of IL6
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Higher baseline levels of IL10
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Higher levels of MCP-1
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Greater proportion of CD45RO(+) T cells (CD4)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Greater proportion of CD45RO(+) T cells (CD8)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Greater expression of CTLA-4 on CD8(+) T cells
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Expression of TIM3 on CD4(+) T cells
Number of subjects: 73
Study: 26719433

Group type: EXPERIMENTAL
Intervention: Blood citrulline
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid binding protein
Number of subjects: 33
Study: 26719803

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47
Study: 26719807

Group type: EXPERIMENTAL
Intervention: FD-OCT
Number of subjects: 12

Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FD-OCT postdilation
Number of subjects: 12

Group type: COMPARATOR
Intervention: IVUS postdilation
Number of subjects: 12
Study: 26719818

Group type: EXPERIMENTAL
Intervention: Biomarker combinations (urinary neutrophil gelatinase lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (l-FABP), interleukin-18 (IL-18))
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Changes in serum creatinine and urine output, cumulative fluid overload (%), serum creatinine corrected for fluid balance, and KDIGO AKI stage
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Biomarker combinations
Number of subjects: 5500
Study: 26720423

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d orally until disease progression, with continuation at discretion after progression.
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Erlotinib continued after progression in 93 patients.
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Erlotinib in patients with exon 19 deletions or L585R mutations.
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Erlotinib therapy overall.
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Erlotinib therapy in safety population (n = 207).
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Plasma-based assessment of EGFR mutations.
Number of subjects: 208
Study: 26720426

Group type: EXPERIMENTAL
Intervention: Upper endoscopy with multistaged esophageal biopsies under general anesthesia
Number of subjects: 120
Study: 26720750

Group type: EXPERIMENTAL
Intervention: Sinus node dysfunction (SND)
Number of subjects: 9631

Group type: COMPARATOR
Intervention: Patients without sinus node dysfunction (Control)
Number of subjects: 9631
Study: 26721814

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26721819

Group type: EXPERIMENTAL
Intervention: Palatinose intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucrose intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26721823

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination introduced in 2006
Number of subjects: 40552

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 40552
Study: 26722126

Group type: EXPERIMENTAL
Intervention: Plasma glycine levels
Number of subjects: 4109

Group type: EXPERIMENTAL
Intervention: Plasma glycine levels in patients with apolipoprotein B, low-density lipoprotein cholesterol, or apolipoprotein A-1 above the median
Number of subjects: 4109
Study: 26723464

Group type: EXPERIMENTAL
Intervention: Lomitapide
Number of subjects: 6
Study: 26723501

Group type: EXPERIMENTAL
Intervention: Olaparib 400mg bid capsule monotherapy
Number of subjects: 193
Study: 26724322

Group type: EXPERIMENTAL
Intervention: B Cell Depletion Therapy
Number of subjects: 0
Study: 26725208

Group type: EXPERIMENTAL
Intervention: Suicide risk screening
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of patient opinions
Number of subjects: 200
Study: 26725209

Group type: EXPERIMENTAL
Intervention: TB < 2.0 mg/dL
Number of subjects: 137

Group type: COMPARATOR
Intervention: TB ≥ 2.0 mg/dL
Number of subjects: 137
Study: 26725459

Group type: COMPARATOR
Intervention: Child Health Questionnaire (CHQ)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Functional Status II (Revised)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: CHQ and Functional Status II
Number of subjects: 355
Study: 26725920

Group type: EXPERIMENTAL
Intervention: PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)
Number of subjects: 379
Study: 26726900

Group type: EXPERIMENTAL
Intervention: Obese group with appropriate cuff sizes based on arm circumferences
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group with appropriate cuff sizes based on arm circumferences
Number of subjects: 104
Study: 26728744

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus octreotide
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: BCI (Breast Cancer Index)
Number of subjects: 299
Study: 26729345

Group type: EXPERIMENTAL
Intervention: Rituximab/Bendamustine (RB) followed by Rituximab/High-dose Cytarabine (RC)
Number of subjects: 23